The therapeutic application of Xanor Depot (alprazolam extended-release) is focused on providing consistent symptomatic relief for specific, distressing anxiety-related conditions.

Management of Recurrent Symptoms

The medication is commonly used to help with conditions presenting with acute episodes, primarily Panic Disorder and Generalized Anxiety Disorder (GAD). It is applied across domains where additional symptomatic support is needed to address symptom clusters that may become intense or disruptive. This medication is used for managing the frequency and intensity of acute episodes, and is relevant for easing the recurrent, unexpected panic attacks and the intense fear and somatic symptoms they cause, such as palpitations and shaking. The primary goal is to provide supportive relief that helps patients cope more steadily with symptom fluctuations, and may help improve day-to-day comfort.

Continuous Symptom Stabilization

The extended-release formulation provides sustained symptomatic support, which may be relevant for conditions that require consistent therapeutic presence. This may assist with maintaining a sense of stability against sudden symptom escalation, and supports patients during difficult episodes.

Quick Fact: Symptomatic Support for Key Anxiety Manifestations
Conditions	Panic Disorder, Generalized Anxiety Disorder (GAD)
Symptom Axes	Excessive psychological tension, recurrent acute fear, somatic distress (e.g., shaking)
Core Benefit	Sustained symptomatic support and assists with maintaining functional stability

Xanor Depot (alprazolam extended-release) is prescribed primarily for the treatment of panic disorder in adults.

---

Who Can Use Xanor Depot?

Appropriate candidates for this medication are typically adult patients diagnosed with panic disorder, with or without agoraphobia. Use in the elderly may be appropriate, but generally requires a lower starting dose and careful monitoring due to increased sensitivity to the sedative effects and potential for accumulation in the presence of reduced kidney or liver function.

---

Who Should Not Use Xanor Depot?

This medication is contraindicated and should not be used in the following patient groups:

• Individuals with a known allergy or hypersensitivity to alprazolam, other benzodiazepines, or any component of the formulation.
• Patients with acute narrow-angle glaucoma.
• Patients taking strong CYP3A inhibitors, such as the antifungal medications ketoconazole or itraconazole, as this can significantly increase the drug levels and risk of serious side effects.

Caution and a thorough review of risks and benefits are essential for patients with a history of substance abuse, depression or suicidal ideation, severe respiratory disease, or impaired liver or kidney function. Furthermore, Xanor Depot is not generally recommended for use during pregnancy or breastfeeding due to potential risks to the fetus or infant. The safety and efficacy of the extended-release formulation in the pediatric population have not been established.

Interactions with other medicines and products

Xanor Depot (alprazolam) is primarily metabolized by the cytochrome P450 3A (CYP3A) enzyme system. This metabolic pathway is the basis for a majority of its clinically significant drug interactions, leading to required dose adjustments or restrictions.

Contraindicated and High-Risk Combinations

• Strong CYP3A Inhibitors: Concomitant use with strong CYP3A inhibitors, such as ketoconazole and itraconazole, is contraindicated. These medicines significantly impede the breakdown of alprazolam, resulting in substantially increased plasma concentrations and a heightened risk of adverse effects.
• Opioids and CNS Depressants: Co-administration with opioids carries a boxed warning due to the risk of profound sedation, respiratory depression, coma, and death. Alcohol and other Central Nervous System (CNS) depressants also produce additive effects and should be avoided.

Other Documented Interactions

Interacting Product Category	Mechanism / Result	Specific Examples Listed
Moderate CYP3A Inhibitors	Increase alprazolam plasma levels (e.g., nefazodone, fluvoxamine, erythromycin).	Nefazodone, Fluvoxamine, Erythromycin, Ritonavir*
CYP3A Inducers	Decrease alprazolam plasma levels, potentially reducing efficacy.	Carbamazepine
Digoxin	Can increase the risk of digoxin toxicity.	Digoxin

*The use with ritonavir is complex and requires specific dose reductions when initiating co-administration, as long-term use may offset the initial inhibition effect.

Positive Allosteric Modulation of GABAA Receptors

This domain covers the drug's primary binding and function as an Positive Allosteric Modulator (PAM) of the mathbfgamma -Aminobutyric acid type A (GABAA) inhibitory receptors . The drug binds to a site separate from the GABA binding site, increasing the frequency of chloride ion channel opening when GABA is present. This mechanism modifies the early molecular step of neurotransmission, resulting in a cellular effect of neuronal hyperpolarization.

Central Nervous System (CNS) Inhibitory Cascade

This domain describes the subsequent cascade where the enhanced GABAA activity increases the influx of chloride ions (Cl^-) into the postsynaptic neurons, thereby dampening neuronal excitability across the brain. This mechanism results in a decrease in overall signal output in key central circuits, which modulates physiological activity.

Modulation of Arousal and Motor Control

This domain focuses on the systemic consequences of the heightened inhibition, particularly within circuits that regulate alertness, muscle tone, and coordination. By engaging mechanisms that increase inhibition within pathways in the limbic system and motor centers, the drug produces the resulting physiological effects of sedation and muscle relaxation.

Administration Guidelines

Xanor Depot is an extended-release tablet designed exclusively for oral administration. The tablet's specialized integrity is critical for its controlled release; therefore, the tablets are intended to be swallowed whole and should not be divided, crushed, or chewed.

Standard Regimen and Frequency

The extended-release formulation is administered once daily, typically taken in the morning to maintain a consistent systemic concentration over a 24-hour period. Dosage initiation for adults generally begins between 0.5 mg and 1 mg per day. The usual daily maintenance range is 3 mg to 6 mg for approved indications. Any adjustment to the daily dose is conducted gradually, occurring at intervals of no less than three or four days, with increments not exceeding 1 mg per day.

Dose Adjustment and Duration

A lower starting dose of 0.5 mg once daily is utilized for certain populations, including older adults and patients with hepatic impairment. The necessity of continuing the medicine is periodically re-evaluated, particularly when administration extends beyond eight weeks. Discontinuation of Xanor Depot involves a structured, gradual tapering process, generally involving a decrease of no more than 0.5 mg every three days to ensure a controlled reduction.

Research evidence / Overview of Studies for Xanor Depot

Evidence for Use in Panic Disorder

Research exploring the use of Xanor Depot (alprazolam extended-release) was primarily conducted through short-term, randomized controlled trials (RCTs). These studies were designed to compare the formulation against an inactive substance, known as a placebo, in adult patients experiencing Panic Disorder. Researchers used these trials to examine specific outcomes, such as how the frequency of panic attacks changed over time and how an individual’s clinical global status was monitored using standardized scales.

In these controlled research settings, studies reported measurements of changes in panic attack frequency during the brief treatment period observed. Studies also monitored how the condition evolved, and some trials described patterns related to the clinical global status. It is noted that the overall pattern of findings was not uniform, as results were mixed across the pool of fixed-dose studies reviewed by regulatory agencies.

---

Long-Term Research and Follow-up Durations

The available research provides context for the effects observed over defined, short time intervals, as the core efficacy trials typically had follow-up durations of only six to eight weeks.

There is limited information for long-term outcomes because regulatory trials did not systematically evaluate the patterns of use or the continuation of effects beyond this initial short-term period. Studies help show what has been observed so far within the trial window, but they do not provide extensive data on the effects or stability of the medication over many months or years.

---

Understanding the Strength and Gaps in the Evidence

The evidence level is broadly categorized as moderate, a grading that is informed by the existing trial data and noted limitations. Reviews of the research have noted that findings were mixed and inconsistent across the full body of trial data submitted to regulators. The follow-up durations were limited in the main efficacy trials, meaning there is limited information regarding what occurs beyond the initial short-term treatment phase.

Common questions about Xanor Depot (FAQ)

Q: How quickly does Xanor Depot start to work after taking it?

The extended-release formulation is designed to release the substance slowly over time, which is different from the rapid peak seen with standard immediate-release formulations. Official product information indicates that the drug maintains a relatively constant level in the body between 5 and 11 hours after administration.

Q: How long does the general feeling of effect from Xanor Depot typically last?

The formulation is intended to deliver sustained therapeutic concentrations over a 24-hour period. Studies show the average elimination half-life (the time it takes for half the substance to leave the body) in healthy adults ranges between approximately 10.7 and 15.8 hours.

Q: Do people often report feeling tired after taking Xanor Depot?

Official clinical trial data indicates that feelings related to tiredness are commonly reported. Sedation, Somnolence (sleepiness), and Fatigue are documented as some of the most frequently occurring adverse events in the official prescribing information.

Q: Is there a high chance of memory issues while using Xanor Depot?

The official labeling notes Memory impairment as a documented adverse event reported in clinical trials. According to regulatory-reviewed clinical trial data, this event was reported in 15.4% of patients.

Q: Can people develop a tolerance to the effects of Xanor Depot over time?

Regulatory documents state that tolerance may develop from continued therapy. Tolerance is a physiological state involving a reduced response to the drug after repeated administration.

Q: What are the main findings from clinical trials regarding Xanor Depot's effectiveness?

Clinical trials reviewed by regulators established the efficacy of the extended-release formulation compared to a placebo. The findings were based on several primary measures, including tracking changes in the frequency of panic attacks and standardized clinical global status scales.

Q: What is the difference in how Xanor Depot and standard Xanax are metabolized by the body?

Studies suggest that the metabolism and elimination of the active substance are similar for both the extended-release and immediate-release formulations. The key distinction lies in the slower rate of absorption provided by the extended-release tablet design.

Q: What information is available about Xanor Depot and breastfeeding?

Official product information states that the substance passes into breast milk. Due to the potential for harmful effects in the infant, such as excessive sleepiness or withdrawal symptoms, official regulatory guidance advises against breastfeeding while using this medication.

Q: What are the official guidelines about stopping Xanor Depot?

Official guidelines specify that discontinuation requires a gradual tapering of the dose to help reduce the risk of withdrawal reactions. The guidelines involve a careful and slow reduction in the dosage over time, as determined by a healthcare provider.

Q: Is the risk of side effects higher when first starting Xanor Depot?

The official label notes that effects related to the central nervous system (CNS) depression, such as drowsiness and problems with coordination, are often most prominent when treatment is initiated.

Q: Is it true that Xanor Depot can cause a feeling of being 'foggy'?

Official labeling includes a number of documented central nervous system side effects that align with this description. These include Confusion, Mental impairment, Amnesia (memory loss), and Disturbance in attention, which are listed as common adverse reactions.

Q: Is Xanor Depot appropriate for use in older adults?

Regulatory information notes that older adults may be more sensitive to the effects of this class of medication, such as dizziness and drowsiness. The half-life of the substance can be longer in this population, and for older adults, official guidance notes that a lower dose may be necessary.

Q: Has Xanor Depot been studied in patients with liver problems?

Studies have evaluated the half-life of the substance in patients with alcoholic liver disease. Findings indicated that the mean half-life was prolonged in this patient group compared to healthy subjects.

Q: Can anxiety symptoms occur while using Xanor Depot?

The adverse event table lists Anxiety itself as a documented side effect that was reported in a small percentage of patients during clinical trials. This is noted in official regulatory documentation.

Q: Is Xanor Depot known to cause weight gain or loss?

Clinical trial data reports that both Weight increased (in 5.1% of patients) and Weight decreased (in 4.3% of patients) are separate documented adverse events associated with the medication.

Q: What common supplements or herbal products are known to interact with Xanor Depot?

Interactions are mainly due to products that affect the CYP3A4 enzyme, which is responsible for metabolizing the substance. Official regulatory guidance specifically advises against consuming grapefruit or grapefruit juice while using the medication.

Q: Is Xanor Depot considered a muscle relaxer?

While the primary pharmacological class is defined as a Benzodiazepine Anxiolytic, the known mechanism of action results in physiological effects that include both sedation and muscle relaxation.

Q: What is the goal of maintenance treatment with Xanor Depot?

Regulatory guidelines state that the necessity of continuing the medicine must be periodically re-evaluated. Following a period of extended freedom from panic attacks, the goal involves a carefully supervised discontinuation attempt to manage the potential for recurrence of symptoms.

Q: Can Xanor Depot be used by people with a history of kidney disease?

The official label notes that changes in the substance's processing have been reported in patients with disease states including impaired kidney function. Official information notes that this population requires careful consideration.

Q: Are there any long-term effects of Xanor Depot that studies have identified?

Official documents indicate that research trials were limited to a short duration (six to eight weeks), and data on the long-term effects and efficacy of the medication beyond those periods is limited.

Q: Does Xanor Depot affect blood pressure?

The label documents that Hypertension (high blood pressure) has been reported as a potential symptom that can occur during the withdrawal phase of the medication.

Q: Is there a link between Xanor Depot and depression?

Depression is listed as a common adverse reaction in the clinical trial data. The prescribing information notes caution that the drug may worsen existing depression and requires careful consideration in affected patient populations.

Q: Are there any known foods or drinks that should be strictly avoided with Xanor Depot?

Alcohol should be avoided due to the potential for severe additive CNS depressant effects. Additionally, regulatory guidance specifically advises against consuming grapefruit or grapefruit juice while using the medication.

Q: What kind of common over-the-counter medicines interact with Xanor Depot?

The primary interactions involve medicines that cause CNS depression (central nervous system depression) or those that inhibit the CYP3A enzyme. These types of interacting products may be found in some common over-the-counter cold, allergy, or sleep aids.

Q: Are there any specific lifestyle changes that are recommended while using Xanor Depot?

Official warnings state that due to the potential for dizziness and drowsiness, caution must be exercised when engaging in hazardous occupations or activities that require complete mental alertness, such as operating machinery or driving a motor vehicle.

Q: Can Xanor Depot affect a person's mood in ways other than reducing anxiety?

The label documents that the substance may affect mood through Paradoxical Reactions, which can include symptoms like increased hostility, aggression, and rage. Depression is also listed as a common adverse event.

Q: Are there specific symptoms that indicate a person should stop taking Xanor Depot immediately?

Official warnings identify symptoms that require immediate medical attention, such as signs of a severe allergic reaction (e.g., swelling of the face, lips, or throat). Other serious symptoms include signs of profound respiratory depression (such as slow, shallow breathing or being hard to wake up).

Q: Is Xanor Depot known to cause any skin-related side effects?

The official label documents that signs of a severe allergic reaction can include hives (a raised, itchy skin rash).

Q: Do other ingredients besides alprazolam affect how Xanor Depot works?

The active ingredient, alprazolam, provides the therapeutic effect. However, the tablet's specialized extended-release formulation is integral to the product, as the tablet's matrix controls the slow and continuous absorption of the substance over time.

Q: If I miss a dose of Xanor Depot, what is the official advice?

Official regulatory guidance regarding a missed dose states that it should be taken as soon as possible, unless it is nearly time for the next scheduled dose. Double doses should not be taken to make up for a forgotten dose.

Q: Does the medicine start working slower if taken with food?

Official information indicates that food has a significant influence on the bioavailability of the extended-release tablet. The timing of a meal can affect the time it takes to reach the maximum concentration in the body.

Q: Are there any known interactions between Xanor Depot and common cold medicines?

The primary concern is with cold medicines that also function as CNS depressants (such as certain cough syrups or antihistamines). Interactions are also possible with medicines that affect the CYP3A enzyme that metabolizes the substance.

Q: How is the research on Xanor Depot generally structured?

The research base reviewed by regulatory agencies primarily consists of short-term, randomized, placebo-controlled trials. These studies were conducted in adults diagnosed with panic disorder to assess efficacy against an inactive substance.

How to Store and Dispose of Xanor Depot?

The storage and disposal requirements for Xanor Depot (alprazolam extended-release) are officially defined in regulatory documents to ensure product stability and prevent misuse.

Storage Requirements

Condition	Requirement
Temperature	Store in a closed container at controlled room temperature.
Protection	Keep away from heat, moisture, and direct light; keep from freezing.
Access	Keep the medication strictly out of the reach of children.

Disposal Requirements

As a federally controlled substance, Xanor Depot requires specific disposal methods to prevent diversion and accidental harm. Unused or outdated medicine should not be kept. Regulatory guidance strongly advises using drug take-back programs or mail-back methods whenever possible. If these are not readily available, and the medication is on the recommended list, immediate flushing may be required to prevent serious harm or death from accidental ingestion, particularly by children.